Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells

Gabriele Zoppoli, Michele Cea, Debora Soncini, Floriana Fruscione, Justine Rudner, Eva Moran, Irene Caffa, Davide Bedognetti, Giulia Motta, Riccardo Ghio, Fabio Ferrando, Alberto Ballestrero, Silvio Parodi, Claus Belka, Franco Patrone, Santina Bruzzone, Alessio Nencioni

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective: The nicotinamide phosphoribosyltransferase (Nampt) inhibitor APO866 depletes intracellular nicotinamide adenine dinucleotide (NAD+) and shows promising anticancer activity in preclinical studies. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to plasma membrane receptors DR4 and DR5 and induces apoptosis via caspase-8 and -10. Here we have explored the interaction between APO866 and TRAIL in leukemia cell lines and in primary B-cell chronic lymphocytic leukemia cells. Materials and Methods: Cells were treated with APO866, TRAIL, or their combination. Viability and mitochondrial transmembrane potential (ΔΨm) were determined by cell staining with propidium iodide and tetramethylrhodamine ethyl ester, respectively, and flow cytometry. Nampt and γ-tubulin levels, as well as caspase-3 cleavage were detected by immunoblotting. DR4 and DR5 expression were assessed by immunostaining and flow cytometry. Caspases were inhibited with zVAD-FMK and zDEVD-FMK; autophagy with 3-methyladenine, LY294002, and wortmannin. Intracellular NAD+ and adenosine triphosphate (ATP) were measured by cycling assays and high-performance liquid chromatography (HPLC), respectively. Results: APO866 induced NAD+ depletion, ΔΨm dissipation, and ATP shortage in leukemia cells, thereby leading to autophagic cell death. TRAIL induced caspase-dependent apoptosis. TRAIL addition to APO866 synergistically increased its activity in leukemia cells by enhancing NAD+ depletion, ΔΨm dissipation, and ATP shortage. No DR5 upregulation at the cell surface in response to APO866 was observed. Remarkably, in healthy leukocytes APO866 and TRAIL were poorly active and failed to show any cooperation. Conclusions: Activation of the extrinsic apoptotic cascade with TRAIL selectively amplifies the sequelae of Nampt inhibition in leukemia cells, and appears as a promising strategy to enhance APO866 activity in hematological malignancies.

Original languageEnglish
Pages (from-to)979-988
Number of pages10
JournalExperimental Hematology
Volume38
Issue number11
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Nicotinamide Phosphoribosyltransferase
Leukemia
Apoptosis
NAD
TNF-Related Apoptosis-Inducing Ligand Receptors
Adenosine Triphosphate
Autophagy
Caspases
Flow Cytometry
Caspase 10
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
Caspase 8
Propidium
Hematologic Neoplasms
B-Cell Chronic Lymphocytic Leukemia
Tubulin
Immunoblotting
Caspase 3
Membrane Potentials

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Molecular Biology
  • Hematology

Cite this

Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. / Zoppoli, Gabriele; Cea, Michele; Soncini, Debora; Fruscione, Floriana; Rudner, Justine; Moran, Eva; Caffa, Irene; Bedognetti, Davide; Motta, Giulia; Ghio, Riccardo; Ferrando, Fabio; Ballestrero, Alberto; Parodi, Silvio; Belka, Claus; Patrone, Franco; Bruzzone, Santina; Nencioni, Alessio.

In: Experimental Hematology, Vol. 38, No. 11, 11.2010, p. 979-988.

Research output: Contribution to journalArticle

Zoppoli, G, Cea, M, Soncini, D, Fruscione, F, Rudner, J, Moran, E, Caffa, I, Bedognetti, D, Motta, G, Ghio, R, Ferrando, F, Ballestrero, A, Parodi, S, Belka, C, Patrone, F, Bruzzone, S & Nencioni, A 2010, 'Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells', Experimental Hematology, vol. 38, no. 11, pp. 979-988. https://doi.org/10.1016/j.exphem.2010.07.013
Zoppoli, Gabriele ; Cea, Michele ; Soncini, Debora ; Fruscione, Floriana ; Rudner, Justine ; Moran, Eva ; Caffa, Irene ; Bedognetti, Davide ; Motta, Giulia ; Ghio, Riccardo ; Ferrando, Fabio ; Ballestrero, Alberto ; Parodi, Silvio ; Belka, Claus ; Patrone, Franco ; Bruzzone, Santina ; Nencioni, Alessio. / Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. In: Experimental Hematology. 2010 ; Vol. 38, No. 11. pp. 979-988.
@article{68c570fe524a49c2bb0005093bac82af,
title = "Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells",
abstract = "Objective: The nicotinamide phosphoribosyltransferase (Nampt) inhibitor APO866 depletes intracellular nicotinamide adenine dinucleotide (NAD+) and shows promising anticancer activity in preclinical studies. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to plasma membrane receptors DR4 and DR5 and induces apoptosis via caspase-8 and -10. Here we have explored the interaction between APO866 and TRAIL in leukemia cell lines and in primary B-cell chronic lymphocytic leukemia cells. Materials and Methods: Cells were treated with APO866, TRAIL, or their combination. Viability and mitochondrial transmembrane potential (ΔΨm) were determined by cell staining with propidium iodide and tetramethylrhodamine ethyl ester, respectively, and flow cytometry. Nampt and γ-tubulin levels, as well as caspase-3 cleavage were detected by immunoblotting. DR4 and DR5 expression were assessed by immunostaining and flow cytometry. Caspases were inhibited with zVAD-FMK and zDEVD-FMK; autophagy with 3-methyladenine, LY294002, and wortmannin. Intracellular NAD+ and adenosine triphosphate (ATP) were measured by cycling assays and high-performance liquid chromatography (HPLC), respectively. Results: APO866 induced NAD+ depletion, ΔΨm dissipation, and ATP shortage in leukemia cells, thereby leading to autophagic cell death. TRAIL induced caspase-dependent apoptosis. TRAIL addition to APO866 synergistically increased its activity in leukemia cells by enhancing NAD+ depletion, ΔΨm dissipation, and ATP shortage. No DR5 upregulation at the cell surface in response to APO866 was observed. Remarkably, in healthy leukocytes APO866 and TRAIL were poorly active and failed to show any cooperation. Conclusions: Activation of the extrinsic apoptotic cascade with TRAIL selectively amplifies the sequelae of Nampt inhibition in leukemia cells, and appears as a promising strategy to enhance APO866 activity in hematological malignancies.",
author = "Gabriele Zoppoli and Michele Cea and Debora Soncini and Floriana Fruscione and Justine Rudner and Eva Moran and Irene Caffa and Davide Bedognetti and Giulia Motta and Riccardo Ghio and Fabio Ferrando and Alberto Ballestrero and Silvio Parodi and Claus Belka and Franco Patrone and Santina Bruzzone and Alessio Nencioni",
year = "2010",
month = "11",
doi = "10.1016/j.exphem.2010.07.013",
language = "English",
volume = "38",
pages = "979--988",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells

AU - Zoppoli, Gabriele

AU - Cea, Michele

AU - Soncini, Debora

AU - Fruscione, Floriana

AU - Rudner, Justine

AU - Moran, Eva

AU - Caffa, Irene

AU - Bedognetti, Davide

AU - Motta, Giulia

AU - Ghio, Riccardo

AU - Ferrando, Fabio

AU - Ballestrero, Alberto

AU - Parodi, Silvio

AU - Belka, Claus

AU - Patrone, Franco

AU - Bruzzone, Santina

AU - Nencioni, Alessio

PY - 2010/11

Y1 - 2010/11

N2 - Objective: The nicotinamide phosphoribosyltransferase (Nampt) inhibitor APO866 depletes intracellular nicotinamide adenine dinucleotide (NAD+) and shows promising anticancer activity in preclinical studies. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to plasma membrane receptors DR4 and DR5 and induces apoptosis via caspase-8 and -10. Here we have explored the interaction between APO866 and TRAIL in leukemia cell lines and in primary B-cell chronic lymphocytic leukemia cells. Materials and Methods: Cells were treated with APO866, TRAIL, or their combination. Viability and mitochondrial transmembrane potential (ΔΨm) were determined by cell staining with propidium iodide and tetramethylrhodamine ethyl ester, respectively, and flow cytometry. Nampt and γ-tubulin levels, as well as caspase-3 cleavage were detected by immunoblotting. DR4 and DR5 expression were assessed by immunostaining and flow cytometry. Caspases were inhibited with zVAD-FMK and zDEVD-FMK; autophagy with 3-methyladenine, LY294002, and wortmannin. Intracellular NAD+ and adenosine triphosphate (ATP) were measured by cycling assays and high-performance liquid chromatography (HPLC), respectively. Results: APO866 induced NAD+ depletion, ΔΨm dissipation, and ATP shortage in leukemia cells, thereby leading to autophagic cell death. TRAIL induced caspase-dependent apoptosis. TRAIL addition to APO866 synergistically increased its activity in leukemia cells by enhancing NAD+ depletion, ΔΨm dissipation, and ATP shortage. No DR5 upregulation at the cell surface in response to APO866 was observed. Remarkably, in healthy leukocytes APO866 and TRAIL were poorly active and failed to show any cooperation. Conclusions: Activation of the extrinsic apoptotic cascade with TRAIL selectively amplifies the sequelae of Nampt inhibition in leukemia cells, and appears as a promising strategy to enhance APO866 activity in hematological malignancies.

AB - Objective: The nicotinamide phosphoribosyltransferase (Nampt) inhibitor APO866 depletes intracellular nicotinamide adenine dinucleotide (NAD+) and shows promising anticancer activity in preclinical studies. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to plasma membrane receptors DR4 and DR5 and induces apoptosis via caspase-8 and -10. Here we have explored the interaction between APO866 and TRAIL in leukemia cell lines and in primary B-cell chronic lymphocytic leukemia cells. Materials and Methods: Cells were treated with APO866, TRAIL, or their combination. Viability and mitochondrial transmembrane potential (ΔΨm) were determined by cell staining with propidium iodide and tetramethylrhodamine ethyl ester, respectively, and flow cytometry. Nampt and γ-tubulin levels, as well as caspase-3 cleavage were detected by immunoblotting. DR4 and DR5 expression were assessed by immunostaining and flow cytometry. Caspases were inhibited with zVAD-FMK and zDEVD-FMK; autophagy with 3-methyladenine, LY294002, and wortmannin. Intracellular NAD+ and adenosine triphosphate (ATP) were measured by cycling assays and high-performance liquid chromatography (HPLC), respectively. Results: APO866 induced NAD+ depletion, ΔΨm dissipation, and ATP shortage in leukemia cells, thereby leading to autophagic cell death. TRAIL induced caspase-dependent apoptosis. TRAIL addition to APO866 synergistically increased its activity in leukemia cells by enhancing NAD+ depletion, ΔΨm dissipation, and ATP shortage. No DR5 upregulation at the cell surface in response to APO866 was observed. Remarkably, in healthy leukocytes APO866 and TRAIL were poorly active and failed to show any cooperation. Conclusions: Activation of the extrinsic apoptotic cascade with TRAIL selectively amplifies the sequelae of Nampt inhibition in leukemia cells, and appears as a promising strategy to enhance APO866 activity in hematological malignancies.

UR - http://www.scopus.com/inward/record.url?scp=78649374522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649374522&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2010.07.013

DO - 10.1016/j.exphem.2010.07.013

M3 - Article

C2 - 20696207

AN - SCOPUS:78649374522

VL - 38

SP - 979

EP - 988

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 11

ER -